Pelvic Floor Muscle Spasm
Conditions
Keywords
Pelvic floor muscle spasm, Pelvic pain, physical therapy, pudendal block
Brief summary
Pelvic floor tension myalgia (PFTM) is increasingly noted in patients with chronic pelvic pain. Pelvic floor physical therapy is typically utilized and is at times combined with other therapies such as botox injections, trigger point injections or pudendal blocks. The investigators' study will randomize newly diagnosed patients with PFTM to weekly . Final patient assessment will be performed at 6 months to assess durability of response. Primary hypothesis: The addition of pudendal blocks to standard pelvic floor physical therapy will result in lower pain and pelvic floor muscle tension scores, lower baseline vaginal pressure and increase pelvic floor strength. Secondary hypothesis: The addition of pudendal blocks to standard pelvic floor physical therapy will result in a lower pain score in a shorter time frame, resulting in faster progress through physical therapy.
Detailed description
Participants will be identified within UC Irvine urogynecology and/or pelvic floor physical therapy practice with the underlying diagnosis of pelvic floor tension myalgia. This diagnosis may be secondary to various underlying etiologies including interstitial cystitis/painful bladder syndrome, vulvodynia, endometriosis, adhesive disease, unknown etiology, etc. At the time of enrollment, participants will be randomized into one of two groups: either standard pelvic floor physical therapy with weekly saline placebo injections or standard pelvic floor physical therapy and weekly pudendal blocks for 6 weeks. Standard physical therapy techniques will be utilized in both groups. Weekly injections of a mixture of a steroid and local anesthetic or saline will be administered depending on the randomization. Injections will be administered by a urogynecology physician. The participant and the treating physical therapist will be blinded to treatment assignment. The participant will be evaluated with for pelvic floor muscle strength and tenderness and will have pain assessed by a visual analog scale at baseline, weekly throughout the study, and at 6 months after study enrollment. Vaginal electromyography will be performed and standardized questionnaires regarding pelvic floor symptoms, quality of life and sexual function will be administered at baseline, after 6 weeks of injections and at 6 months after enrollment.
Interventions
8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
5ml of saline at each block site.
Sponsors
Study design
Eligibility
Inclusion criteria
* Non-pregnant women over the age of 18 with the diagnosis of pelvic floor tension myalgia that are naive to pelvic floor physical therapy. * Able to provide informed consent. * Subjects must be willing to accept randomization.
Exclusion criteria
* Previously treated with physical therapy. * An allergy to any component within the pudendal block. * Bleeding disorders. * Active vaginal infection. * Inability to complete the questionnaires. * Inability to read English (validated questionnaires are available in English only). * Inability to complete the follow-up visits.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Pain Score After 6 Weekly Injections | up to 8 weeks | 10 point likert scale to report pain a score from zero for no pain to ten for the worst possible pain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in Pelvic Floor Symptoms as Assessed Through Validated Questionnaires | up to 6 months | The Pelvic Floor Distress Inventory (PFDI) has 20 items and 3 scales, the response scale is from 0-4. Summary scores range from 0-300 with higher scores indicating more distress. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Pudendal Block 8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
Pudendal block: 8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site. | 28 |
| Placebo 5ml of saline at each block site
Placebo: 5ml of saline at each block site. | 12 |
| Total | 40 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 6 | 0 |
Baseline characteristics
| Characteristic | Placebo | Total | Pudendal Block |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 12 Participants | 40 Participants | 28 Participants |
| Age, Continuous | 45 years STANDARD_DEVIATION 4 | 46 years STANDARD_DEVIATION 3 | 46 years STANDARD_DEVIATION 3 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) White | 10 Participants | 33 Participants | 23 Participants |
| Region of Enrollment United States | 12 participants | 40 participants | 28 participants |
| Sex: Female, Male Female | 12 Participants | 40 Participants | 28 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 4 / 22 | 4 / 12 |
| serious Total, serious adverse events | 0 / 22 | 0 / 12 |
Outcome results
Visual Analog Pain Score After 6 Weekly Injections
10 point likert scale to report pain a score from zero for no pain to ten for the worst possible pain
Time frame: up to 8 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pudendal Block | Visual Analog Pain Score After 6 Weekly Injections | 3.33 Visual Analog Pain Score | Standard Deviation 1.87 |
| Placebo | Visual Analog Pain Score After 6 Weekly Injections | 2.99 Visual Analog Pain Score | Standard Deviation 2.03 |
Improvement in Pelvic Floor Symptoms as Assessed Through Validated Questionnaires
The Pelvic Floor Distress Inventory (PFDI) has 20 items and 3 scales, the response scale is from 0-4. Summary scores range from 0-300 with higher scores indicating more distress.
Time frame: up to 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pudendal Block | Improvement in Pelvic Floor Symptoms as Assessed Through Validated Questionnaires | 47.2 score on a scale | Standard Deviation 30.8 |
| Placebo | Improvement in Pelvic Floor Symptoms as Assessed Through Validated Questionnaires | 38.2 score on a scale | Standard Deviation 29 |